Newly released preclinical data to be presented in a poster on November 8, 2025 SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (OTC PINK: CERO) (“CERo” or the “Company”), an innovative cellular immunotherapy company pursuing new targets and novel phagocytic mechanisms, announces it will be presenting data on its lead compound CER-1236 at the Society for Immunotherapy of Cancer (SITC) conference being held November 5-9, 2025 in National Harbor, Md. The poster ...

Company’s Shares Will Continue to Trade Under Ticker CERO on the OTC Markets SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (OTC PINK: CERO) (“CERo” or the “Company”), an innovative cellular immunotherapy company developing novel T cell therapeutics that incorporate phagocytic mechanisms, announces its shares continue to be listed on the public markets under the ticker symbol CERO. Effective as of market open on Friday, October 31, 2025, the Company is listed ...

Core Points - CERo Therapeutics Holdings, Inc. will have its shares suspended from trading on Nasdaq starting October 31, 2025, following a determination by the Nasdaq Hearings Panel to deny the company's request for continued listing [1] - The company plans to appeal the Panel's decision and is seeking to trade its shares on the OTC Markets while continuing its clinical operations [1][5] Financial Compliance - CERo has struggled to comply with Nasdaq Listing Rule 5550(b)(1), which requires a minimum stockholders' equity of $2.5 million [2] - In April 2025, the company believed it had regained compliance after a financing round that included the issuance of Series D Convertible Preferred Stock valued at $5 million [2] - However, due to difficulties in valuing Marketable Securities, the company sold them at a substantial discount, leading to a determination of non-compliance with the Equity Rule [3][4] Panel Decision - The Nasdaq Panel's decision was based on a retroactive assessment of non-compliance as of April 22, 2025, disregarding the company's plans for future compliance [4] - The company has executed parts of its compliance plan, including receiving approximately $2.25 million from the sale of Series E Convertible Preferred Stock and subscriptions for an additional $4.75 million [4] Future Plans - CERo has submitted a request for review of the Panel's decision and is exploring trading on the OTC Markets, although this market is less liquid than Nasdaq [5] - The company intends to continue its clinical trials, specifically for its lead product candidate, CER-1236, which has shown promising early-stage results in patients with AML [6][7] - CERo is reviewing its cash resources and potential financing alternatives to support ongoing operations [7] Company Overview - CERo is focused on developing next-generation engineered T cell therapeutics for cancer treatment, utilizing a unique approach that combines innate and adaptive immunity [8] - The company's proprietary technology aims to enhance tumor targeting through Chimeric Engulfment Receptor T cells (CER-T), which may offer advantages over existing CAR-T therapies [8]

Company completes first tranche of a $7 million financing to increase cash runway and maintain Nasdaq compliance SOUTH SAN FRANCISCO, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo” or the “Company”), an innovative cellular immunotherapy company developing novel T cell therapeutics that incorporate phagocytic mechanisms, today announced that investigators have been authorized under the study protocol to administer a third infusion of CER-1236 to a patient e ...

Core Insights - CERo Therapeutics Holdings, Inc. is participating in a stem cell therapy panel at the Maxim Growth Summit on October 22-23, 2025, in New York City [1][2] - The panel will be moderated by Jason McCarthy, Ph.D., Senior Managing Director at Maxim Group [2] - Chris Ehrlich, CEO of CERo, will be available for one-on-one meetings during the conference [3] Company Overview - CERo is an innovative immunotherapy company focused on developing next-generation engineered T cell therapeutics for cancer treatment [4] - The company’s proprietary T cell engineering approach integrates characteristics of both innate and adaptive immunity, aiming to optimize cancer therapy [4] - CERo's Chimeric Engulfment Receptor T cells (CER-T) are designed to redirect patient-derived T cells to eliminate tumors using phagocytic mechanisms, potentially allowing broader therapeutic applications than current CAR-T therapies [4] - Clinical trials for CERo's lead product candidate, CER-1236, targeting hematological malignancies have commenced [4]

Study’s Dose Escalation Safety Committee approves initiation of Cohort 2 with fourth patient to receive increase in initial dose pending regulatory approval Company issues correction of recently published article, asserts it is not for sale and is not currently actively seeking partnerships as it continues dose finding clinical activities for CER-1236 SOUTH SAN FRANCISCO, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”), an innovative cellu ...

Third patient in the first cohort is now advancing through protocol-defined evaluations as Company anticipates additional results from second dosing of second patient in the cohort SOUTH SAN FRANCISCO, Calif, Sept. 22, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo” or the “Company”), an innovative cellular immunotherapy company, today announced that it has dosed the third patient in the starting dose cohort of its Phase 1 clinical trial evaluating CER-1236 in acute myeloid ...

Core Insights - The health care sector is experiencing a trend of oversold stocks, presenting potential investment opportunities in undervalued companies [1] Group 1: Oversold Stocks - Summit Therapeutics Inc (SMMT) has an RSI value of 22.4, with a stock price of $19.44 and a 52-week low of $15.55, having fallen approximately 31% over the past month [6] - Lunai Bioworks Inc (RENB) has an RSI value of 29.3, with a stock price of $0.19 and a 52-week low of $0.18, experiencing a decline of around 23% over the past five days [6] - CERo Therapeutics Holdings Inc (CERO) has an RSI value of 16.3, with a stock price of $4.68 and a 52-week low of $4.27, having dropped about 37% over the past five days [6]

Core Insights - CERo Therapeutics Holdings, Inc. has received a Notice of Allowance from the U.S. Patent and Trademark Office for its patent application 19/019,111, which will provide composition of matter protection for CER-1236 and its use in cancer treatment until 2041 [1][3] - The company has also secured a patent in Japan, increasing its total to 20 granted patents and allowed applications covering CER-1236 and its platform technology internationally [2] Company Overview - CERo is focused on developing next-generation engineered T cell therapeutics for cancer treatment, utilizing a proprietary approach that integrates characteristics of both innate and adaptive immunity [4] - The company’s lead product candidate, CER-1236, is currently undergoing Phase 1 clinical trials for hematological malignancies [4] Intellectual Property and Regulatory Position - The company’s intellectual property portfolio has been strengthened with the recent patent allowances, enhancing its regulatory position and exclusivity in the market [3] - CERo has also received Fast Track and Orphan Drug Designations from the FDA, further solidifying its regulatory advantages [3]

Core Insights - CERo Therapeutics Holdings, Inc. has administered a second dose in the second patient of its Phase 1 CER-1236 clinical trial for acute myeloid leukemia (AML), with the new protocol allowing for double the cell product infusion compared to the previous approach [1][3] - The study aims to evaluate the safety and preliminary efficacy of CER-1236 in various AML patient populations, including those who are relapsed/refractory or newly diagnosed with TP53 mutated MDS/AML [3][4] - The recent protocol modification is expected to provide valuable insights into dosing, safety, and feasibility as the study progresses [3] Company Overview - CERo is focused on developing next-generation engineered T cell therapeutics for cancer treatment, utilizing a proprietary approach that integrates characteristics of both innate and adaptive immunity [4] - The company’s lead product candidate, CER-1236, is designed to redirect patient-derived T cells to eliminate tumors through phagocytic mechanisms, potentially offering advantages over existing CAR-T therapies [4] Clinical Trial Details - The Phase 1/1b study is structured in two parts: an initial dose escalation phase to determine the highest tolerated dose, followed by an expansion phase to evaluate safety and efficacy [3] - Primary outcome measures include the incidence of adverse events, dose-limited toxicities, and overall response rates, while secondary measures focus on pharmacokinetics [3]